1742-4690-7-S1-I31 1742-4690 Invited speaker presentation <p>Bone ageing and HIV</p> Mallon W Patrick paddy.mallon@ucd.ie

University College Dublin School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, Dublin, Ireland

Retrovirology <p>16<sup>th </sup>International Symposium on HIV and Emerging Infectious Diseases</p> Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1742-4690-7-S1-info.pdf <p>16<sup>th </sup>International Symposium on HIV and Emerging Infectious Diseases</p> Marseille, France 24-26 March 2010 http://www.isheid.com/site/-10ISHEID,671-?lang=eng 1742-4690 2010 7 Suppl 1 I31 http://www.retrovirology.com/content/7/S1/I31 10.1186/1742-4690-7-S1-I31
11 5 2010 2010 Mallon; licensee BioMed Central Ltd.

As HIV-infected patients live longer they are experiencing diseases normally associated with ageing, sometimes at higher frequency and at younger ages than expected. Low bone mineral density (BMD) and osteoporosis is one example. Rates of low BMD are high in HIV-infected patients and fracture rates occur more commonly and at a younger age than the general population. Factors thought to contribute to low BMD in HIV include HIV infection itself, exposure to antiretroviral therapy (ART) and over-representation of traditional risk factors (such as smoking, hypogonadism and low body mass index) for low BMD in HIV-infected populations. Current evidence suggests that patients lose BMD after ART initiation and, to some extent, with switch in ART. Rates of BMD loss appear higher when protease inhibitors or some NRTI are used as part of the initial ART regimen. This presentation will outline current data on low BMD in HIV, discuss ways of monitoring for low BMD and current approaches to management of this common condition.